DENVER, Colo. (247marketnews.com) — The market is serving up a powerful mix of movers, including Alaunos Therapeutics (NASDAQ:TCRT) completed a major acquisition backed by a $350 million private placement, while NeOnc Technologies Holdings (NASDAQ:NTHI) is preparing for an important FDA discussion. Verastem Oncology (NASDAQ:VSTM) reported fresh cancer-drug results alongside a major financing and leadership transition, and Liquidia (NASDAQ:LQDA) resolved a prolonged legal battle over its pulmonary-hypertension treatment. Bending Spoons (NASDAQ:BSP) is attracting another major investment from Berkshire Hathaway.
Alaunos Therapeutics- $350 Million Financing Fuels Major Biotech Transformation
Alaunos Therapeutics (NASDAQ:TCRT) made a dramatic strategic pivot with its October 13 announcement that it completed the acquisition of Velaris Therapeutics, a privately held biotechnology company developing treatments for pulmonary arterial hypertension (PAH) and related cardiopulmonary diseases. The transaction gives Alaunos a portfolio of investigational biologics designed to target signaling pathways involved in pulmonary vascular remodeling. The deal represents a substantial change in the company’s development strategy, shifting attention toward a pipeline with multiple potential clinical milestones.
The acquisition was accompanied by a $350 million private placement led by Fairmount, with participation from a syndicate of institutional biotechnology investors. According to the company, the financing is expected to support operations into 2029, fund development of Velaris’s pipeline and provide capital to advance programs toward clinical proof-of-concept data and initial regulatory filings. The planned milestones include clinical data for VLR199 and VLR360, as well as potential investigational new drug filings for VLR247 and VLR258. These programs remain investigational, and their safety and efficacy have not been established.
NeOnc- Abu Dhabi Expansion and FDA Talks Put Brain-Cancer Pipeline in Focus
NeOnc (NASDAQ:NTHI) strengthened its leadership as it advances therapies targeting cancers of the central nervous system. The company appointed Ali Alabedin, Head of Islamic Banking Group at First Abu Dhabi Bank, Dubai’s largest and most influential bank, to its Board of Directors effective October 9, 2026. His more than three decades of international banking and executive experience add financial governance and international-growth expertise as NeOnc pursues clinical-development opportunities in Abu Dhabi.
The strategic backdrop is the company’s NEO212 program, which has completed Phase 1 dose escalation and is moving toward Phase 2 development. Abu Dhabi’s Department of Health has granted investigational new drug authorization supporting development in the UAE, subject to required ethics approvals and other pre-enrollment conditions.
NeOnc has also reported positive topline results from its 24-patient NEO100 Phase 2a study. On August 12, the company reported six-month progression-free survival of 48.9%, compared with a prespecified 20% benchmark, and median overall survival of 26.09 months. The company also announced redemption of its outstanding Series A convertible preferred stock in September, saying it eliminated the related potential dilution without issuing common shares.
The next key milestone is the November 17, 2026, End-of-Phase 1 Type B meeting with the U.S. Food and Drug Administration regarding NEO212. Discussions are expected to cover potential Phase 2 design, patient population, endpoints and regulatory pathways. Investors should also monitor UAE ethics clearance, trial readiness and subsequent NEO100 regulatory engagement.
Verastem Oncology- New Cancer Data, $250 Million Offering and CEO Transition Raise the Stakes
Verastem Oncology (NASDAQ:VSTM) delivered a consequential set of announcements, combining new clinical results for its investigational KRAS G12D inhibitor VS-7375 with a planned leadership transition and a substantial capital raise. The company reported a 50% confirmed objective response rate in second-line pancreatic ductal adenocarcinoma patients treated with the 900-milligram once-daily regimen. It also reported a 41% confirmed response rate across the broader second-line-and-later pancreatic cancer population treated at that dose.
The company also reported results in other cancer settings, including a 43% confirmed response rate with 600 milligrams once daily in second-line-and-later non-small cell lung cancer. Verastem said it has reached FDA alignment on the Phase 3 trial design for first-line metastatic pancreatic cancer and plans to open that trial by year-end. The next phase will test whether the promising response signals translate into durable benefits in larger studies.
Alongside the clinical update, Verastem announced the pricing of an underwritten offering expected to generate approximately $250 million in gross proceeds before underwriting discounts and other expenses. The offering consists of 30,937,500 common shares priced at $8.00 each and pre-funded warrants covering up to 312,503 additional shares.
The company also announced that CEO Daniel Paterson plans to step down, with Michael Bailey expected to succeed him on January 1, 2027. That leadership transition arrives as Verastem prepares to advance VS-7375 and continues developing its marketed Avmapki Fakzynja Co-Pack treatment for recurrent low-grade serous ovarian cancer. The next major catalyst is the planned Phase 3 launch, followed by further clinical data. Investors will need to weigh the potential of VS-7375 against clinical risk, competition and the implications of the new financing.
Liquidia- $380.7 Million Settlement Ends Major Legal Battle
Liquidia (NASDAQ:LQDA) removed a significant source of uncertainty by reaching a global settlement with United Therapeutics, resolving six lawsuits tied to Yutrepia, its inhaled treprostinil treatment for pulmonary hypertension. Announced October 13, the agreement settles a prolonged dispute involving patent, trade-secret, contract and antitrust claims. The resolution is consequential because the litigation had threatened the commercial future of Yutrepia, a key product in Liquidia’s growth strategy.
Under the settlement, Liquidia can continue commercializing Yutrepia for pulmonary arterial hypertension (PAH), but it will stop marketing the product for pulmonary hypertension associated with interstitial lung disease (PH-ILD) and terminate the related clinical trials. Liquidia agreed to pay United Therapeutics a net $380.7 million in installments during 2026 and 2027. The arrangement provides clarity on the company’s commercial path, but the payment obligation is substantial and will affect its financial planning.
The company also received FDA Fast Track designation for Yutrepia in Raynaud’s phenomenon associated with systemic sclerosis in September, potentially opening another development pathway. The settlement now narrows the focus to PAH commercialization, the financial implications of the agreement and the longer-term prospects of its pipeline, including investigational L606.
Bending Spoons- Berkshire Hathaway Adds $330 Million to Its Bet on Digital-Tech Acquirer
Bending Spoons (NASDAQ:BSP) is attracting fresh institutional attention after Berkshire Hathaway (NYSE:BRK.B) announced an additional $330 million investment, which lifts Berkshire’s ownership to approximately 4%, following its earlier $600 million investment at Bending Spoons’ July 2026 IPO. The new transaction involves the issuance of 10 million shares to Berkshire at $33 each, providing fresh capital for the company’s acquisition-driven strategy.
The Milan-based technology company has built its business around acquiring digital products and improving their operations, monetization and technology. Its portfolio includes recognizable businesses such as AOL, Vimeo, Evernote, Eventbrite, Brightcove, WeTransfer and others. Rather than relying solely on organic growth, Bending Spoons seeks to acquire established digital properties, optimize their operations and use the resulting earnings to fund further acquisitions.
About 24/7 Market News
In today’s fast-moving markets, visibility is everything and 24/7 Market News (24/7) provides a powerful suite of investor relations and public relations solutions designed to elevate your company’s profile quickly and effectively. Whether you’re an established name seeking broader awareness, or a micro-cap looking to break out of obscurity, 24/7 delivers targeted, high-impact coverage through timely news distribution, analyst report placements, featured editorials, and multi-channel amplification across financial platforms, social media, and investor communities. Our services help cut through the noise, attract institutional interest, drive exposure, and build long-term shareholder credibility, all while maintaining full SEC compliance and transparency. For Analyst Report coverage, custom IR campaigns, press release syndication, or other tailored investor and public relations solutions, contact sales@247mnn.com to discuss how 24/7 can help accelerate your company’s visibility and valuation trajectory.
PAID EDITORIAL DISCLOSURE: This is a paid editorial communication intended for informational purposes only. 24/7 is compensated by NTHI to provide ongoing news coverage of expected upcoming catalysts and events as well as market outreach services. For further disclosure information, please click here. This should not be construed as financial or investment advice. Trading involves substantial risk; consult your financial advisor.
Important Editorial Note: 247 highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.
CONTACT:
24/7 Market News
Editor@247mnn.com
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements that are subject to various risks and uncertainties. Such statements include statements regarding the Company’s ability to grow its business and other statements that are not historical facts, including statements which may be accompanied by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Actual results could differ materially from those described in these forward-looking statements due to a number of factors, including without limitation, the Company’s ability to continue as a going concern, general economic conditions, and other risk factors detailed in the Company’s filings with the SEC. The forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake any responsibility to update such forward-looking statements except in accordance with applicable law.